公开(公告)号：US11918550B2

公开(公告)日：2024-03-05

申请号：US17542145

申请日：2021-12-03

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Jiangbin Ye ,  Haowen Jiang ,  Yang Li

IPC分类号： A61K31/167 ,  A61K31/06 ,  A61K31/203 ,  A61K31/225 ,  A61P35/00

CPC分类号： A61K31/167 ,  A61K31/06 ,  A61K31/203 ,  A61K31/225 ,  A61P35/00

摘要： Methods are provided for the treatment of cancer by administering a mitochondrial uncoupler in a dose effective to increase differentiation of the cancer cells, which may be provided in a combination with a retinoic acid to differentiate the cancer cells. The effect on the targeted cancer cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used. The cancer may be resistant to retinoic acid.

公开(公告)号：US20230265193A1

公开(公告)日：2023-08-24

申请号：US18046300

申请日：2022-10-13

申请人： KYOTO UNIVERSITY

发明人： Tasuku Honjo ,  Kenji CHAMOTO ,  Sidonia FAGARASAN

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K31/06 ,  A61K31/122 ,  A61K31/275 ,  A61K31/327 ,  A61K31/53 ,  A61K31/661 ,  A61K39/395 ,  A61K31/045 ,  A61P31/04 ,  A61P35/00

CPC分类号： C07K16/2818 ,  A61K31/045 ,  A61K31/06 ,  A61K31/122 ,  A61K31/275 ,  A61K31/327 ,  A61K31/53 ,  A61K31/661 ,  A61K39/395 ,  A61K45/06 ,  A61P31/04 ,  A61P35/00 ,  A61P33/00

摘要： A novel therapeutic strategy for the anti-PD-1 antibody therapy is provided. A pharmaceutical composition which comprises at least one substance selected from the group consisting of the following (i) to (iii) and is administered before, after or simultaneously with the administration of a PD-1 signal inhibitor: (i) ROS generators and substances that regulate downstream signaling pathways thereof, (ii) substances exhibiting an uncoupling effect and substances that regulate downstream signaling pathways thereof, and (iii) amino acids.

公开(公告)号：US11497720B2

公开(公告)日：2022-11-15

申请号：US15188131

申请日：2016-06-21

申请人： SEPTEOS

发明人： Nicolas Tesse

IPC分类号： A61K31/11 ,  A61K31/045 ,  A61K45/06 ,  A61K31/235 ,  A61K31/222 ,  A61K31/352 ,  A61K31/015 ,  A61K47/02 ,  A61K9/06 ,  A61K31/22 ,  A61K9/00 ,  A61K31/06 ,  A61K47/26 ,  A61K31/08 ,  A61K31/37 ,  A61K47/10 ,  A61K47/32 ,  A61K31/04 ,  A01N27/00 ,  A01N31/02 ,  A01N37/02 ,  A01N37/10 ,  A01N43/90

摘要： This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

公开(公告)号：US11464753B2

公开(公告)日：2022-10-11

申请号：US16252212

申请日：2019-01-18

申请人： WINNING THE FIGHT INC.

发明人： Vincent M Tedone

IPC分类号： A61K31/122 ,  A61K31/19 ,  A61K31/194 ,  A61K31/197 ,  A61K31/205 ,  A61K31/22 ,  A61K31/7084 ,  A61K31/06 ,  A61K45/06

摘要： A composition of matter comprising an α-ketoglutarate (AKG) or an α-ketoglutaric acid or a salt of an α-ketoglutarate may be used to treat patients having a neurodegenerative disease, such as amyotrophic lateralsclerosis. The composition may be administered hourly or may be administered once a day depending on the size and activity of the patient and the release coating or mechanism provided. In addition to AKG, a core composition may comprise GABA and a source of coenzyme Q10. Other substances may be provided either orally or intravenous in addition to the core composition, as required to control symptoms, or in order to stimulate stem cells to add motor neurons.

公开(公告)号：US11117874B2

公开(公告)日：2021-09-14

申请号：US16855522

申请日：2020-04-22

申请人： AstraZeneca AB

发明人： Hans Roland Lonn ,  Stephen Connolly ,  Steven Swallow ,  Staffan PO Karlsson ,  Carl-Johan Aurell ,  John Fritiof Pontén ,  Kevin James Doyle ,  Amanda Jane Van De Poël ,  Graham Peter Jones ,  David Wyn Watson ,  Jaqueline Anne Macritchie ,  Nicholas John Palmer

IPC分类号： A61K31/553 ,  A61K31/06 ,  A61P11/00 ,  C07D267/10 ,  C07D409/10 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  A61K45/06

摘要： The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

公开(公告)号：US10463772B2

公开(公告)日：2019-11-05

申请号：US14323235

申请日：2014-07-03

申请人： ALLERGAN, INC.

发明人： Michael R. Robinson ,  Hui Liu ,  Patrick M. Hughes ,  Lon T. Spada ,  Alazar N. Ghebremeskel

IPC分类号： A61K31/06 ,  A61L31/06 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/216 ,  A61K31/557 ,  A61K31/5575 ,  A61L31/16

摘要： Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.

公开(公告)号：US10363257B2

公开(公告)日：2019-07-30

申请号：US15875678

申请日：2018-01-19

申请人： ZENITH EPIGENETICS LTD.

发明人： John Frederick Quinn ,  Bryan Cordell Duffy ,  Shuang Liu ,  Ruifang Wang ,  May Xiaowu Jiang ,  Gregory Scott Martin ,  Gregory Steven Wagner ,  Peter Roland Young

IPC分类号： A61K31/5377 ,  A61K31/06 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/517 ,  A61K31/52 ,  A61K31/4184 ,  A61K31/4985 ,  A61K31/4545 ,  C07D413/04 ,  C07D471/04 ,  C07D473/34 ,  A61K45/06

摘要： The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

公开(公告)号：US20190054085A1

公开(公告)日：2019-02-21

申请号：US16166101

申请日：2018-10-21

申请人： Glytech LLC

发明人： Daniel C. Javitt

IPC分类号： A61K31/496 ,  A61K31/42 ,  A61K31/551 ,  A61K31/135 ,  A61K31/431 ,  A61K31/519 ,  A61K31/4525 ,  A61K31/553 ,  A61K45/06 ,  A61K31/138 ,  A61K31/381 ,  A61K31/55 ,  A61K31/554 ,  A61K31/06

摘要： This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.

公开(公告)号：US20180263976A1

公开(公告)日：2018-09-20

申请号：US15987932

申请日：2018-05-24

申请人： Glytech LLC

发明人： Daniel C. Javitt

IPC分类号： A61K31/496 ,  A61K31/138 ,  A61K45/06 ,  A61K31/42 ,  A61K31/55 ,  A61K31/554 ,  A61K31/06 ,  A61K31/135 ,  A61K31/381 ,  A61K31/431 ,  A61K31/4525 ,  A61K31/519 ,  A61K31/551 ,  A61K31/553

CPC分类号： A61K31/496 ,  A61K31/06 ,  A61K31/135 ,  A61K31/138 ,  A61K31/381 ,  A61K31/42 ,  A61K31/431 ,  A61K31/4525 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K45/06 ,  A61K2300/00

摘要： This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

公开(公告)号：US09821173B2

公开(公告)日：2017-11-21

申请号：US14176848

申请日：2014-02-10

申请人： Case Western Reserve University

发明人： Anthony J. Berdis

IPC分类号： A61K31/404 ,  A61N5/10 ,  A61K41/00 ,  A61K31/28 ,  A61K31/06 ,  C07F9/50 ,  C07F1/12

CPC分类号： A61N5/10 ,  A61K31/06 ,  A61K31/28 ,  A61K31/404 ,  A61K41/0038 ,  A61N2005/1098 ,  C07F1/12 ,  C07F9/5045

摘要： An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.